13. Geno KA, Gilbert GL, Song JY, et al. Pneumococcal capsules and their types: past, present, and future. Clin Microbiol Rev 2015; 28: 871-899.
14. Hausdorff WP, Feikin DR, Klugman KP. Epidemiological differences among pneumococcal serotypes. Lancet Infect Dis 2005; 5: 83-93.
15. Kadioglu A, Weiser J, Paton J, Andrew P. The role of Streptococcus pneumoniae virulence factors in host respiratory colonization and disease. Nat Rev Microbiol 2008; 6: 288-301.
16. Simell B, Auranen K, Kayhty H, Goldblatt D, Dagan R, O’Brien KL. The fundamental link between pneumococcal carriage and disease. Expert Rev Vaccines 2012; 11: 841-855.
17. Jochems SP, Weiser JN, Malley R, Ferreira DM. The immunological mechanisms that control pneumococcal carriage. PLoS pathogens 2017; 13: e1006665.
18. Rodrigues F, Danon L, Morales-Aza B, et al. Pneumococcal serotypes colonise the nasopharynx in children at different densities. PLoS One 2016; 11: e0163435.
19. Rodríguez MAG, González AV, Gavín MAO, et al. Invasive pneumococcal disease: association between serotype, clinical presentation and lethality. Vaccine 2011; 29: 5740-5746.
20. Johnson HL, Deloria-Knoll M, Levine OS, et al. Systematic evaluation of serotypes causing invasive pneumococcal disease among children under five: the pneumococcal global serotype project. PLoS Med 2010; 7: e1000348.
21. Klein DL. Pneumococcal conjugate vaccines: review and update. Microb Drug Resist 1995; 1: 49-58.
22. Feldman C, Anderson R. Review: current and new generation pneumococcal vaccines. J Infect 2014; 69: 309-325.
23. Pletz MW, Maus U, Krug N, Welte T, Lode H. Pneumococcal vaccines: mechanism of action, impact on epidemiology and adaption of the species. Int J Antimicrob Agents 2008; 32: 199-206.
24. Hausdorff W, Bryant J, Paradiso P, Siber G. Which pneumococcal serogroups cause the most invasive disease: implications for conjugate vaccine formulation and use, part I. Clin Infect Dis 2000; 30: 100-121.
25. Hausdorff WP, Bryant J, Kloek C, Paradiso PR, Siber GR. The contribution of specific pneumococcal serogroups to different disease manifestations: implications for conjugate vaccine formulation and use, part II. Clin Infect Dis 2000; 30: 122-140.
26. Australian Technical Advisory Group on Immunisation. Australian immunisation handbook. Canberra: Australian Government Department of Health; 2018.
27. Pilishvili T, Zell ER, Farley MM, et al. Risk factors for invasive pneumococcal disease in children in the era of conjugate vaccine use. Pediatrics 2010; 126: e9-e17.
28. van Hoek AJ, Andrews N, Waight P, et al. The effect of underlying clinical conditions on the risk of developing invasive pneumococcal disease in England. J Infect 2012; 65: 17-24.
29. Hsu KK, Shea KM, Stevenson AE, Pelton SI. Underlying conditions in children with invasive pneumococcal disease in the conjugate vaccine era. Pediatr Infect Dis J 2011; 30: 251-253.
30. Yildirim I, Shea K, Little B, Silverio A, Pelton S. Vaccination, underlying comorbidities, and risk of invasive pneumococcal disease. Pediatrics 2015; 135: 495-503.
31. Centers for Disease Control and Prevention (CDC). Pneumococcal disease. In: Atkinson W, Wolfe S, Hamborsky J, eds. Epidemiology and prevention of vaccine-preventable diseases. 12th ed. Washington, DC: Public Health Foundation; 2011: p. 233-247.